PMID- 21668473
OWN - NLM
STAT- MEDLINE
DCOM- 20120217
LR  - 20151119
IS  - 1365-2559 (Electronic)
IS  - 0309-0167 (Linking)
VI  - 59
IP  - 3
DP  - 2011 Sep
TI  - Oestrogen receptor/progesterone receptor and human epidermal growth factor 
      receptor 2 status in breast cancer: a 9-year study at Princess Noorah Oncology 
      Center, Saudi Arabia.
PG  - 537-42
LID - 10.1111/j.1365-2559.2011.03883.x [doi]
AB  - OBJECTIVE: To determine the oestrogen receptor/progesterone receptor (ER/PR) and 
      human epidermal growth factor receptor 2 (HER2) status in Saudi Arabian patients 
      presenting with breast cancer to Princess Noorah Oncology Center (PNOC) and to 
      explore the correlation of these markers to each other, to tumour type and to 
      grade. METHODS AND RESULTS: Pathology material and records of symptomatic 
      patients presenting to the centre during 2001-2009 were reviewed for patients' 
      age, tumour size, type and grade and ER/PR and HER2 immunohistochemistry (IHC) 
      status using the Dako HercepTest Kit as well as fluorescence in situ 
      hybridization (FISH) for HER2 IHC 2+ score cases, as per the 2007 American 
      Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) 
      guidelines. There were 852 cases, with a mean age of 49years and a mean tumour 
      size of 3.0 cm with 75% node positivity. Of all cases, 772 (90.6%) were ductal 
      carcinoma; 64% were ER/PR(+) and 23% were HER2(+); triple-negative cases 
      accounted for 24%. CONCLUSIONS: ER/PR and HER2 status did not differ from that 
      reported previously, showing a direct correlation to tumour type and grade of 
      ductal carcinoma. However, a difference exists in the relatively lower ER 
      positivity in patients aged >50 years and the higher percentage of 
      triple-negative cases. This study would serve as a baseline for other future 
      national studies and for planning strategies to targeted therapy.
CI  - (c) 2011 Blackwell Publishing Limited.
FAU - Satti, Mohamed B
AU  - Satti MB
AD  - Department of Pathology and Laboratory Medicine, King Saud Bin Abdulaziz 
      University for Health Sciences/National Guard Health Affairs, National Guard 
      Hospital - Western Region, Jeddah, Saudi Arabia. sattimb@ngha.med.sa
LA  - eng
PT  - Journal Article
DEP - 20110613
PL  - England
TA  - Histopathology
JT  - Histopathology
JID - 7704136
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Receptors, Estrogen)
RN  - 0 (Receptors, Progesterone)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Biomarkers, Tumor/*analysis
MH  - Breast Neoplasms/genetics/*metabolism
MH  - Female
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Middle Aged
MH  - Neoplasm Grading
MH  - Receptor, ErbB-2/*biosynthesis/genetics
MH  - Receptors, Estrogen/*biosynthesis/genetics
MH  - Receptors, Progesterone/*biosynthesis/genetics
MH  - Saudi Arabia
MH  - Young Adult
EDAT- 2011/06/15 06:00
MHDA- 2012/02/18 06:00
CRDT- 2011/06/15 06:00
PHST- 2011/06/15 06:00 [entrez]
PHST- 2011/06/15 06:00 [pubmed]
PHST- 2012/02/18 06:00 [medline]
AID - 10.1111/j.1365-2559.2011.03883.x [doi]
PST - ppublish
SO  - Histopathology. 2011 Sep;59(3):537-42. doi: 10.1111/j.1365-2559.2011.03883.x. 
      Epub 2011 Jun 13.